Two FDA-Cleared PLAC® Tests

As pioneers in the testing of Lp-PLA2, a validated marker of cardiovascular risk, we have a portfolio of commercially-available PLAC® Tests, the only two FDA-cleared tests to measure Lp-PLA2.

Capabilities and Product Portfolio for Growth

Our extensive capabilities, from development to commercialization, enable our evolution into a multi-product company delivering actionable information to healthcare providers for patient management.

Recent News

September 8, 2015

Diadexus, Inc. and OriGene Technologies Sign Exclusive License Agreement for the Development and Commercialization of PLAC(R) ELISA in Asia

August 13, 2015

Diadexus, Inc. Reports Second Quarter 2015 Financial Results